Oncology Research

TLA is based on proximity ligation and yields complete sequence information across the targeted locus, including SNVs and structural variants.


Since TLA uses the physical proximity of sequences as the basis of selection and is based on the crosslinking and fragmenting of DNA, it has particular advantages in the detection of structural variation in FFPE samples.


Cergentis is currently developing TLA protocols for FFPE samples (see press release).


Complete cancer gene sequencing is highly relevant for different applications in oncology, such as:


  • Detecting gene fusions with recurrent and novel fusion partners.
  • Determining the gene fusion breakpoints at DNA level, which can serve as a robust and sensitive marker for ctDNA monitoring.
  • Complete sequencing of tumour suppressor genes to detect all mutations including deletions and promoter/intronic events.
  • Analyzing complex rearrangements, genomic events underlying CNVs and novel resistance mechanisms.



  • "Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”

    Princess Máxima Center for Pediatric Oncology

    Dr. Jules Meijerink - Principal Investigator (Utrecht, The Netherlands)

  • "We conclude that TLA is an effective method for the reliable detection of sequence mutations and structural variations that are relevant for disease prognosis in pediatric leukemia.”

                                  Princess Máxima Center for Pediatric Oncology                              

    Dr. Roland Kuiper - Senior PI (Utrecht, The Netherlands)

  • "Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”

                                    Ghent University                                  

    Prof. Dr. Pieter van Vlierberghe - Center for Medical Genetics (Belgium)

  • Application notes
  • Publications
  • Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study

    Meisel C et al. (2017)                                                                                                            

    DKFZ, Medical Genetic Center Munich, National Center for Tumor Diseases (NCT), TU Dresden, University Kiel

  • Activating ESR1 Mutations Differentially Impact the Efficacy of ER Antagonists

    Toy W et al. (2019)                                                                                                                             

    AstraZeneca, Memorial Sloan Kettering Cancer Center, University of Chicago & University of Illinois at Urbana Champaign

  • Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

    Ter Brugge P et al. (2016)                                                                                                            

    Bellvitge Biomedical Research Institute Barcelona, Curie Institute, ICREA, Institute of Cancer Research London, The Netherlands Cancer Institute, University of Barcelona & University Medical Center Utrecht

  • Sequencing Structural Variants in Cancer for Precision Therapeutics

    Macintyre G et al. (2016)                                                                                                            

    University of Cambridge & VU University Medical Center

  • Guidelines for cytogenetic investigations in tumours

    Hastings RJ et al. (2015)                                                                                                            

    Charles University Prague, CHUV, Great Ormond St Hospital, Gustave Roussy, Hospital del Mar, Institute of Genomic Medicine, Oslo University Hospital, Ospedale di Circolo-Polo Universitario, Our Lady's Children's Hospital, Oxford University Hospitals NHS Trust, Radboud University Medical Center, St James's Hospital, University of Cagliari, University of Groningen, University Hospital Ghent, UZ Leuven, VU University Medical Center

© 2012-2019 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.